Actively Recruiting
The Effects of Caregiver Training on DTTC Treatment Outcomes in CAS
Led by New York University · Updated on 2026-01-20
40
Participants Needed
2
Research Sites
180 weeks
Total Duration
On this page
Sponsors
N
New York University
Lead Sponsor
H
Hofstra University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to investigate the impact of direct vs. indirect caregiver training on treatment outcomes following a period of Dynamic Temporal and Tactile Cueing (DTTC) intervention combined with home practice in childhood apraxia of speech (CAS). Forty children with CAS, between the ages of 2;5 and 7;11 years of age, will be recruited for this study. All children will receive DTTC treatment at the frequency of standard care (2x/week) in a university clinic over and 8-week period. Participants will be randomly assigned to one of two groups: the Direct Training Group; the Indirect Training Group. All caregivers will complete an educational module about CAS, will observe all sessions, and will engage in home practice with their children. Caregivers in the Direct Group will receive coaching in the use of DTTC with their child during a portion of each treatment session to support home practice, whereas those in the Indirect Group will not receive detailed guidance for home practice. Caregivers in both groups will practice at home with their children during the treatment phase (3x/week). Following the treatment phase, home practice will continue at a higher frequency (6x/week) during a 4-week follow-up phase. Treatment outcomes will be compared between groups.
CONDITIONS
Official Title
The Effects of Caregiver Training on DTTC Treatment Outcomes in CAS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child aged between 2 years 6 months and 7 years 11 months at the start of treatment
- English is the primary and preferred language
- Primary speech diagnosis of Childhood Apraxia of Speech based on expert diagnosis or DEMSS score showing significant evidence of CAS (score below 323)
You will not qualify if you...
- Diagnosis of autism spectrum disorder, global developmental delay, intellectual disability, Down syndrome, or other genetic conditions (ADHD allowed if child can attend sessions with medication or strategies)
- Primary diagnosis of dysarthria or other speech sound disorders such as phonological impairment
- Presence of oral structural anomalies
- Hearing impairment
- Uncorrected visual impairment
- Receiving speech treatment elsewhere during the study (language or AAC treatment allowed)
- Receptive Language Index standard score below 70 on REEL-4, CELF-P3, or CELF-5 tests as appropriate
- Cognitive standard score below 70 on DAYC (ages 2-5) or Reynolds Intellectual Assessment Scales (ages 6-7)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hofstra University
Hempstead, New York, United States, 11549
Actively Recruiting
2
New York University
New York, New York, United States, 10012
Actively Recruiting
Research Team
M
Maria I Grigos, PhD
CONTACT
J
Julie Case, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here